“Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program”, J of Skin, vol. 7, no. 6, p. s291, Nov. 2023, doi: 10.25251/skin.7.supp.291.